Core Insights - COEPTIS, Inc. has formed a majority-owned subsidiary, GEAR Therapeutics, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for various cancers and therapeutic modalities [1] - The GEAR™ Cell Therapy Platform offers a first-in-class approach to modifying immune cells, aiming to enhance remission rates in patients with hematologic malignancies and other cancers [1] - GEAR-NK cells are designed to be co-administered with targeted monoclonal antibodies, potentially improving treatment outcomes by avoiding neutralization by mAb therapy [2][3] Company Developments - COEPTIS has successfully licensed exclusive worldwide development and commercialization rights to the GEAR platform from VyGen-Bio, Inc., expanding its ownership and capabilities in the biotechnology sector [1][4] - The company is focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, with a commitment to improving patient outcomes through advanced research [5][6] - COEPTIS has established a Technology Division to enhance operational capabilities, incorporating AI-powered marketing software and robotic process automation tools [7] Market Potential - The GEAR technology is expected to address significant therapeutic needs in the market, providing a cost-effective option for patients requiring advanced cancer therapies [4] - The GEAR platform also has the potential to modify hematopoietic stem cells in combination with mAbs, which could improve bone marrow transplant outcomes for hematological malignancies [2]
Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline